MX365590B - Metodos para preparar 6-(aril o heteroaril)-1,3,5-triazin-2,4-diol es y 6-(aril o heteroaril)-1,3,5-triazin-2,4-diaminas. - Google Patents

Metodos para preparar 6-(aril o heteroaril)-1,3,5-triazin-2,4-diol es y 6-(aril o heteroaril)-1,3,5-triazin-2,4-diaminas.

Info

Publication number
MX365590B
MX365590B MX2018001424A MX2018001424A MX365590B MX 365590 B MX365590 B MX 365590B MX 2018001424 A MX2018001424 A MX 2018001424A MX 2018001424 A MX2018001424 A MX 2018001424A MX 365590 B MX365590 B MX 365590B
Authority
MX
Mexico
Prior art keywords
triazine
heteroaryl
aryl
methods
preparing
Prior art date
Application number
MX2018001424A
Other languages
English (en)
Spanish (es)
Other versions
MX2018001424A (es
Inventor
Zhang Shijie
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Publication of MX2018001424A publication Critical patent/MX2018001424A/es
Publication of MX365590B publication Critical patent/MX365590B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
MX2018001424A 2015-08-05 2016-08-04 Metodos para preparar 6-(aril o heteroaril)-1,3,5-triazin-2,4-diol es y 6-(aril o heteroaril)-1,3,5-triazin-2,4-diaminas. MX365590B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562201546P 2015-08-05 2015-08-05
PCT/US2016/045553 WO2017024134A1 (en) 2015-08-05 2016-08-04 Methods of preparing 6-(aryl or heteroaryl)-1,3,5-triazine-2,4-diols and 6-(aryl or heteroaryl)-1,3,5-triazine-2,4-diamines

Publications (2)

Publication Number Publication Date
MX2018001424A MX2018001424A (es) 2018-08-01
MX365590B true MX365590B (es) 2019-06-07

Family

ID=56684781

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018001424A MX365590B (es) 2015-08-05 2016-08-04 Metodos para preparar 6-(aril o heteroaril)-1,3,5-triazin-2,4-diol es y 6-(aril o heteroaril)-1,3,5-triazin-2,4-diaminas.

Country Status (8)

Country Link
US (1) US9751863B2 (enExample)
EP (1) EP3331866B1 (enExample)
JP (2) JP6816106B2 (enExample)
CN (1) CN108349933A (enExample)
AU (2) AU2016303614A1 (enExample)
CA (1) CA2993615A1 (enExample)
MX (1) MX365590B (enExample)
WO (1) WO2017024134A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3200800A1 (en) 2014-09-29 2017-08-09 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2016126798A1 (en) 2015-02-04 2016-08-11 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
EP3331866B1 (en) * 2015-08-05 2023-07-26 Les Laboratoires Servier Methods of preparing a 6-heteroaryl-1,3,5-triazine-2,4-diol and a 6-heteroaryl-1,3,5-triazine-2,4-diamine
MX381582B (es) 2015-10-15 2025-03-12 Celgene Corp Terapia de combinacion para el tratamiento de neoplasias malignas.
CA3001599A1 (en) 2015-10-15 2017-04-20 Agios Pharmaceuticals, Inc. Combination therapy for treating malignancies
IL298663A (en) 2015-12-04 2023-01-01 Agios Pharmaceuticals Inc Methods for treating acute myeloid leukemia characterized by the presence of a mutant allele of idh2 and the absence of a mutant allele of nras
WO2017146795A1 (en) 2016-02-26 2017-08-31 Agios Pharmaceuticals, Inc. Idh1 inhibitors for the treatment of haematological malignancies and solid tumours
JP2019529534A (ja) 2016-09-07 2019-10-17 セルジーン コーポレイション 錠剤組成物
EP3618828B1 (en) 2017-05-05 2023-11-01 Memorial Sloan Kettering Cancer Center Methods of treatment of myeloproliferative neoplasm
US20220017489A1 (en) 2018-11-02 2022-01-20 Celgene Corporation Solid dispersions for treatment of cancer
US20220017490A1 (en) 2018-11-02 2022-01-20 Celgene Corporation Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof
US12215094B2 (en) 2018-11-02 2025-02-04 Celgene Corporation Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol
WO2021097160A1 (en) 2019-11-14 2021-05-20 Celgene Corporation Pediatric formulations for treatment of cancer
CN111592524B (zh) * 2020-05-20 2023-11-17 温州市天聚万迅信息科技有限公司 恩西德尼的制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2390529A (en) 1942-02-03 1945-12-11 Ernst A H Friedheim Hydrazino-1,3,5-triazino derivatives of substituted phenylarsenic compounds
JPS5170779A (ja) * 1974-12-17 1976-06-18 Nippon Shinyaku Co Ltd Shinkinaguanamidoruino seiho
JPS58186682A (ja) 1982-04-27 1983-10-31 日本化薬株式会社 セルロ−ス又はセルロ−ス含有繊維材料の染色法
DE3512630A1 (de) 1985-04-06 1986-10-23 Hoechst Ag, 6230 Frankfurt Verfahren zum faerben oder bedrucken von cellulosefasern oder cellulosemischfasern
ATE130882T1 (de) 1990-07-12 1995-12-15 Ciba Geigy Ag Verfahren zur photochemischen und thermischen stabilisierung von polyamid-fasermaterialien.
JPH11158073A (ja) 1997-09-26 1999-06-15 Takeda Chem Ind Ltd アデノシンa3拮抗剤
EP1187825A1 (en) 1999-06-07 2002-03-20 Shire Biochem Inc. Thiophene integrin inhibitors
HUE029020T2 (en) 2002-07-18 2017-02-28 Janssen Pharmaceutica Nv Substituted triazine kinase inhibitors
EP2152676B1 (en) 2007-04-30 2013-04-03 ProMetic BioSciences Inc. "triazine derivatives, compositions containing such derivatives, and methods of treatment of cancer and autoimmune diseases using such derivatives"
GB0805477D0 (en) 2008-03-26 2008-04-30 Univ Nottingham Pyrimidines triazines and their use as pharmaceutical agents
US20120238576A1 (en) 2009-06-08 2012-09-20 California Capital Equity, Llc Triazine Derivatives and their Therapeutical Applications
LT2800743T (lt) * 2012-01-06 2018-06-25 Agios Pharmaceuticals, Inc. Terapiškai aktyvūs junginiai ir jų panaudojimo būdai
CN104169260A (zh) 2012-03-09 2014-11-26 卡尔那生物科学株式会社 新三嗪衍生物
ES2807582T3 (es) 2013-07-11 2021-02-23 Agios Pharmaceuticals Inc Compuestos N,6-bis(aril o heteroaril)-1,3,5-triazina-2,4-diamina como inhibidores de mutantes IDH2 para el tratamiento del cáncer
WO2015003360A2 (en) * 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015017821A2 (en) 2013-08-02 2015-02-05 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
EP3200800A1 (en) 2014-09-29 2017-08-09 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2016126798A1 (en) 2015-02-04 2016-08-11 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
EP3331866B1 (en) * 2015-08-05 2023-07-26 Les Laboratoires Servier Methods of preparing a 6-heteroaryl-1,3,5-triazine-2,4-diol and a 6-heteroaryl-1,3,5-triazine-2,4-diamine

Also Published As

Publication number Publication date
AU2016303614A1 (en) 2018-02-15
AU2021200494A1 (en) 2021-03-11
US9751863B2 (en) 2017-09-05
CA2993615A1 (en) 2017-02-09
EP3331866B1 (en) 2023-07-26
EP3331866A1 (en) 2018-06-13
JP2018528182A (ja) 2018-09-27
CN108349933A (zh) 2018-07-31
JP6816106B2 (ja) 2021-01-20
WO2017024134A1 (en) 2017-02-09
US20170037031A1 (en) 2017-02-09
JP2021063097A (ja) 2021-04-22
MX2018001424A (es) 2018-08-01

Similar Documents

Publication Publication Date Title
MX2018001424A (es) Metodos para preparar 6-(aril o heteroaril)-1,3,5-triazin-2,4-diol es y 6-(aril o heteroaril)-1,3,5-triazin-2,4-diaminas.
ZA201906111B (en) Cyclic di-nucleotides compounds for the treatment of cancer
MY202026A (en) Compounds useful as kinase inhibitors
PH12018501151A1 (en) Tank-binding kinase inhibitor compounds
PH12017502090A1 (en) Heterocyclic amides as kinase inhibitors
GEP20186933B (en) Substituted dihydroisoquinoline compounds
PH12017501825B1 (en) Bicyclic quinazolinone derivatives
PH12016500055A1 (en) N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as idh2 mutants inhibitors for the treatment of cancer
PH12018500457A1 (en) New phenoxymethyl derivatives
JOP20190254A1 (ar) مركبات مضادة للأورام
MY198613A (en) Nitrobenzyl derivatives of anti-cancer agents
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
MX2017003930A (es) Derivados de aminotriazina utiles como compuestos inhibidores de la cinasa de union a tank.
TN2018000020A1 (en) Colony stimulating factor-1 receptor (csf-1r) inhibitors.
MY198325A (en) Prodrugs for the Treatment of Cancer
PH12015502611A1 (en) Heterocyclic compounds as hedgehog signaling pathway inhibitors
EA201790327A1 (ru) Соединения замещенного пиперидина
MX2016009663A (es) Derivados de icariina.
CY1120763T1 (el) Νεες ενωσεις σουλφονυλαμινοβενζαμιδιου
MX2019001979A (es) Agonista de ppar? para el tratamiento de neoplasias hematicas.
MX2016016840A (es) Nuevas pirazolil-triazolil-piridinas como agentes plaguicidas.
MX2019002017A (es) Derivados de sofosbuvir para el tratamiento de la hepatitis c.
HUE053358T2 (hu) 5-Metil-6-fenil-4,5-dihidro-2H-piridazin-3-on származék agytumorok kezelésére
MX2016010268A (es) Pirimidinimidazolaminas como modulares de actividad de cinasa.
GB2564185A (en) Process for the preparation of derivatives of benzodioxole

Legal Events

Date Code Title Description
FG Grant or registration